Literature DB >> 6779679

Oxygen therapy, oxygen therapy in medical patients hospitalized outside of the intensive care unit.

G L Snider, J E Rinaldo.   

Abstract

The administration of O2-enriched breathing mixtures to acutely ill patients is based on the premise that this form of treatment can overcome the known deleterious effects of tissue hypoxia. Therapeutic practices are founded on a knowledge of the physiology of oxygenation in normal and diseased persons and on knowledge of pulmonary O2 toxicity rather than on demonstrated alterations in disease outcome. The arterial PO2 (Pao2), when markedly diminished, indicates O2 deprivation of tissues, especially in unstable or acute states. However, th Pao2 may show little or no abnormality in states with sharply diminished generalized or regional systemic blood flow. Despite these shortcomings, the Pao2 remains a useful guide for initiating and monitoring O2 therapy in many circumstances. To minimize pulmonary O2 toxicity, the concentration of O2 chosen should be the lowest dose that will correct hypoxemia; 40% O2 is not known to be clinically toxic even after prolonged administration, but toxicity increases progressively above this value. In hypoxemic eucapnic patients, Pao2 of 60 mm Hg represents a reasonable value for treatable hypoxemia, but it is often rational to treat unstable patients with higher Pao2 values, especially if the alveolar-arterial Po2 difference is abnormally wide; 40% O2 represents a reasonable initial dose, with adjustments made on the basis of serial Pao2 measurements. When hypercapnia accompanies hypoxemia, O2 is often not given for Pao2 values greater than 50 mm Hg, and controlled low-dose O2 (24 to 30%) should be used to correct hypoxemia partially while preserving an element of hypoxemic ventilatory drive. In states of low blood flow, high O2 concentrations should be used to maximize the amount of O2 dissolved in plasma, and the duration of therapy should be as brief as possible to minimize O2 toxicity.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6779679     DOI: 10.1164/arrd.1980.122.5P2.29

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  5 in total

1.  Development, dissemination, implementation and evaluation of a clinical pathway for oxygen therapy.

Authors:  C Wong; F Visram; D Cook; L Griffith; J Randall; B O'Brien; D Higgins
Journal:  CMAJ       Date:  2000-01-11       Impact factor: 8.262

Review 2.  Hyperoxia-induced signal transduction pathways in pulmonary epithelial cells.

Authors:  Tahereh E Zaher; Edmund J Miller; Dympna M P Morrow; Mohammad Javdan; Lin L Mantell
Journal:  Free Radic Biol Med       Date:  2007-01-17       Impact factor: 7.376

Review 3.  Acute oxygen therapy: a review of prescribing and delivery practices.

Authors:  Joyce L Cousins; Peter A B Wark; Vanessa M McDonald
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-05-24

4.  Familiarity of Physicians and Nurses with Different Aspects of Oxygen Therapy; a Brief Report.

Authors:  Reza Goharani; MirMohammad Miri; Mehran Kouchek; Mohammad Sistanizad
Journal:  Emerg (Tehran)       Date:  2017-01-11

5.  The α7 nicotinic acetylcholine receptor agonist, GTS-21, attenuates hyperoxia-induced acute inflammatory lung injury by alleviating the accumulation of HMGB1 in the airways and the circulation.

Authors:  Ravikumar A Sitapara; Alex G Gauthier; Sergio I Valdés-Ferrer; Mosi Lin; Vivek Patel; Mao Wang; Ashley T Martino; Jeanette C Perron; Charles R Ashby; Kevin J Tracey; Valentin A Pavlov; Lin L Mantell
Journal:  Mol Med       Date:  2020-06-29       Impact factor: 6.354

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.